Generative AI-Enabled Lead Scoring Drives $120M+ Revenue for Clinical Research Organisation

A clinical research organisation's business development team used to spend weeks turning a single trial opportunity into an outreach plan. QuantSpark's generative AI-enabled lead-scoring system compressed that cycle to around 30 minutes. On the strength of that speed and prioritisation, the organisation projects more than $120M in incremental revenue over the following 12 months, an implied return above 100 times programme cost. That figure is a projection, not an audited outturn, so it sits alongside results that are already delivered: $127M awarded in new business pipeline and an 80-fold increase in lead-scoring speed that frees five to eight days a month of research time per sales representative.

Before QuantSpark's involvement, the organisation's constraint was not appetite for growth but the mechanics of finding and pursuing the right opportunities. Deal origination was entirely manual: representatives had to research each prospective clinical trial and cross-reference it against the organisation's own capabilities before building a case for outreach, a process that took weeks per opportunity. In a market where clinical trial sponsors run competitive, time-boxed requests for proposal, a multi-week research cycle is itself a competitive disadvantage, leaving less time to build a compelling case before a faster-moving competitor could engage the sponsor.

Two further problems compounded the delay. Sales decisions were being made on limited market insight, so genuinely good-fit opportunities were plausibly missed or under-prioritised simply because nobody had the bandwidth to surface them systematically. And leadership had no consolidated, data-based view of the pipeline. Without a scoring or ranking layer to sit above individual deals, management was working from anecdote rather than a structured picture of where proposals stood or where effort should be concentrated.

QuantSpark's response combined conventional machine learning scoring with a generative AI layer built specifically for the clinical domain. External market and trial indicators were first mapped onto the organisation's existing data, widening what the model had to work with beyond internal records alone. A medically specialised generative AI was then used to map the organisation's own capabilities against the requirements of upcoming clinical trials, a matching task suited to language-model reasoning and poorly suited to manual review at any scale. Finally, a lead-scoring engine combined the enriched data with the generative AI's fit assessment to automatically score and rank every live opportunity, pushing a prioritised list straight to the business development team in place of ad hoc research.

The effect was to replace a multi-week, largely manual research cycle with an on-demand model run of about 30 minutes: an 80-fold increase in raw scoring speed, equivalent to five to eight days a month of research time returned to each sales representative. The same ranked output also gave leadership the consolidated pipeline view that had been missing. A structured, data-based list of scored opportunities is itself a reporting layer, so the visibility gap closed alongside the speed gain rather than needing a separate fix.

The commercial results split cleanly into two categories. Delivered, process-level results include the $127M awarded in new business pipeline, the 80x lead-scoring speed increase, an approximate 25% increase in RFP value and a 10% increase in response rate. Modelled, forward-looking results sit apart: the organisation projects the system will drive more than $120M in incremental revenue over the next 12 months, implying a return above 100 times programme cost. That is the organisation's own estimate rather than a verified outcome, and the pipeline size, win-rate assumptions and cost base behind the calculation are not disclosed in public material.

For a reader weighing up the story, the more durable proof point is process rather than the projection. A research task that once took a sales representative more than 40 hours now runs in roughly 30 minutes, and the organisation has already booked $127M of pipeline off the back of it. The $120M figure is the upside case; the operational metrics are the evidence that makes it credible.